Table 2.
Comparison of treatment and responsiveness in two groups.
| Characteristics | NS group (n = 85) | Non-NS group (n = 85) | p value |
|---|---|---|---|
| Treatment | |||
| RAASi only (%) | 5 (5.9%) | 15 (17.6%) | 0.02 |
| Corticosteroid (%) | 79 (92.9%) | 65 (76.5%) | 0.003 |
| Corticosteroid combined with Immunosuppressive agents (%) | 61 (71.8%) | 49 (57.6%) | 0.05 |
| Cyclophosphamide | 33 (38.8%) | 26 (30.6%) | 0.59 |
| Mycophenolate mofetil | 17 (20%) | 11 (12.9%) | 0.21 |
| Ciclosporin | 16 (18.8%) | 8 (9.4%) | 0.08 |
| Tacrolimus | 3 (3.5%) | 5 (5.9%) | 0.47 |
| Leflunomide | 11 (12.9%) | 13 (15.3%) | 0.66 |
| Tripterygium wilfordii | 11 (12.9%) | 15 (17.6%) | 0.39 |
| Proteinuria remission | |||
| CR/PR/NR | 24/38/23 | 12/53/20 | 0.04 |
| CR + PR/NR | 62/23 | 65/20 | 0.72 |
CR, Complete remission; PR, Partial remission; NR, no remission or disease progression; RAASi, Renin—angiotensin—aldosterone system inhibitors.